VLKIM
VRTX icon

Van Lanschot Kempen Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Van Lanschot Kempen Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-257
Closed -$117K – 262
2025
Q4 		$117K Buy
257
+16
+7% +$6.9K ﹤0.01% 239
2025
Q3 		$94.4K Sell
241
-422
-64% -$176K ﹤0.01% 242
2025
Q2 		$295K Sell
663
-35
-5% -$16.1K ﹤0.01% 233
2025
Q1 		$338K Sell
698
-2,682
-79% -$1.25M ﹤0.01% 218
2024
Q4 		$1.36M Sell
3,380
-59
-2% -$27.3K 0.01% 208
2024
Q3 		$1.6M Sell
3,439
-247
-7% -$119K 0.02% 185
2024
Q2 		$1.73M Sell
3,686
-1,000
-21% -$434K 0.02% 188
2024
Q1 		$1.96M Sell
4,686
-1,847
-28% -$781K 0.02% 179
2023
Q4 		$2.66M Sell
6,533
-1,206
-16% -$446K 0.04% 170
2023
Q3 		$2.69M Sell
7,739
-1,276
-14% -$446K 0.05% 147
2023
Q2 		$3.17M Sell
9,015
-3,710
-29% -$1.25M 0.06% 147
2023
Q1 		$4.01M Buy
12,725
+797
+7% +$239K 0.08% 135
2022
Q4 		$3.44M Buy
11,928
+1,154
+11% +$352K 0.1% 127
2022
Q3 		$3.12M Sell
10,774
-605
-5% -$174K 0.13% 116
2022
Q2 		$3.21M Buy
11,379
+440
+4% +$118K 0.12% 119
2022
Q1 		$2.85M Buy
10,939
+10,694
+4,365% +$2.54M 0.09% 128
2021
Q4 		$54K Hold
245
– – ﹤0.01% 181
2021
Q3 		$44K Buy
245
+30
+14% +$5.86K ﹤0.01% 194
2021
Q2 		$43K Buy
+215
New +$45K ﹤0.01% 195

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Van Lanschot Kempen Investment Management's VRTX Position: Q1 2026 in Review

Van Lanschot Kempen Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 257 shares — an estimated $117K sold.

Van Lanschot Kempen Investment Management first reported a position in VRTX in Q2 2021 and held it in 19 quarters. The position peaked at $4.01M in Q1 2023. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Van Lanschot Kempen Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Van Lanschot Kempen Investment Management sold 257 Vertex Pharmaceuticals shares in Q1 2026, an estimated $117K.
  • Van Lanschot Kempen Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 19 quarters.
  • Van Lanschot Kempen Investment Management's Vertex Pharmaceuticals position peaked at $4.01M in Q1 2023.
  • 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.